Sign inJoin waitlistJoin the waitlist

Anastasia Martynova

Assistant Professor of Clinical Medicine · University of Southern California/Los Angeles General Medical Center

Credentials: · · · · ·

History

University of Southern California/Los Angeles General Medical Center
Present

University of Southern California
2020–2023
University of Southern California
2017–2020
Doctor of Medicine
2008–2012

Research

Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series
Clinical Lymphoma · 2018 · 27 citations
Telomerase Variants in Patients with Cirrhosis Awaiting Liver Transplantation
Hepatology · 2019 · 13 citations
Proinflammatory macrophages release CXCL5 to regulate T cell function and limit effects of αPD-1 in steatosis-driven liver cancer
JHEP Reports · 2025 · 9 citations

Anthony El-Khoueiry
5 papers
Karam Ashouri
4 papers · 4 as a resident
Casey O'Connell
3 papers
CN
Christina Nakhoul
3 papers · 3 as a resident
Liyun Yuan
3 papers
Ali Rastegarpour
2 papers
AC
April Choi
2 papers · 2 as a fellow
Caitlin O'Neill
2 papers · 2 as a fellow
CC
Catherine Chan
2 papers · 1 as a resident
George Yaghmour
2 papers
Hadi Erfani
2 papers · 2 as a fellow
Janice Liebler
2 papers

Clinical trials

A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
Principal investigator · Recruiting
University of Southern California
2024–2030
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
Principal investigator · Recruiting · Phase 1, Phase 2
University of Southern California
2020–2027
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Marengo Therapeutics, Inc.
2025–2028
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2021–2026